Willingness to utilize supervised injection facilities among people who inject drugs in Iran: Findings from 2020 national HIV bio-behavioral surveillance survey

Supervised injection facilities (SIFs) have not yet been integrated into Iran's harm reduction programs. This study aimed to report the extent to which people who inject drugs (PWID) in Iran are willing to use SIFs. Participants were recruited from 11 major cities using respondent-driven sampli...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of drug policy 2021-11, Vol.97, p.103355-103355, Article 103355
Main Authors: Khezri, Mehrdad, Karamouzian, Mohammad, Sharifi, Hamid, Ghalekhani, Nima, Tavakoli, Fatemeh, Mehmandoost, Soheil, Mehrabi, Fatemeh, Pedarzadeh, Marjan, Nejat, Mehdi, Noroozi, Alireza, Baral, Stefan, Shokoohi, Mostafa
Format: Article
Language:English
Subjects:
Blood diseases
Drug policy
Drug use
Drugs
Food security
Harm reduction
Health services
Healthy food
Hepatitis
Hepatitis C
HIV
Homeless people
Human immunodeficiency virus
Imprisonment
Insecurity
Iran
Needle sharing
People who inject drugs
Sampling
Stimulants
Supervised injection facilities
Surveillance
Well being
Willingness
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Supervised injection facilities (SIFs) have not yet been integrated into Iran's harm reduction programs. This study aimed to report the extent to which people who inject drugs (PWID) in Iran are willing to use SIFs. Participants were recruited from 11 major cities using respondent-driven sampling. Willingness to use SIFs was defined as a three-level categorical variable: low, moderate, or high. Of 2,490 PWID, 52.8% and 23.8% reported high and moderate willingness to use SIFs, respectively. PWID with a history of homelessness (relative-risk ratio (RRR): 2.22, 95% CI: 1.76–2.80), incarceration (1.86 [1.48–2.35]), hepatitis C infection (1.49 [1.13–1.97]), and non-fatal overdose (2.30 [1.69–3.13]) were more likely to be willing to utilize SIFs. Willingness to use SIFs was also higher among PWID who reported recent public injecting (2.24 [1.70–2.97]), daily injection (1.82 [1.35–2.45]), stimulants injection (2.39 [1.41–4.07]), syringe sharing (3.09 [1.23-7.74]), harm reduction services utilization (2.80 [2.13–3.68]), and food insecurity (8.28 [5.43-12.63]). The majority of PWID in Iran expressed willingness to use SIFs, in particular, those who were involved in higher-risk injection practices, dealing with structural risks, and had experienced drug-related harms. SIFs represent critical opportunities to deliver comprehensive harm reduction services to improve the health and well-being of PWID in Iran.
ISSN:0955-3959
1873-4758
DOI:10.1016/j.drugpo.2021.103355